Wave Life Sciences reported Q2 2026 financial results, highlighting progress in its RNA medicine pipeline. The company initiated Phase 2a dosing of WVE-007 for obesity, showing promise in fat loss and cardiometabolic benefits. It also advanced RNA editing programs WVE-006 for alpha-1 antitrypsin deficiency and WVE-008 for PNPLA3 liver disease, with FDA discussions planned for accelerated approval. Wave ended Q2 with $490.6 million in cash, supporting operations into Q3 2028 despite a net loss of $69.4 million for the quarter. Upcoming milestones include Phase 2 trials for obesity combinations and investor updates in fall 2026.
Grab's Chief Product Officer has sold 30,000 shares, generating $109,200 from the transaction. This insider sale may indicate personal financial planning or a strategic move, but it does not necessarily reflect the company's overall performance. Inve...
On September 5, 2026, 600 bitcoins mined in 2010 were transferred from 12 original wallets to new addresses, totaling about $47.84 million at current prices. These coins are from Bitcoin's earliest mining days, before it had a market price, making th...
The TRON blockchain ecosystem has exceeded 402 million accounts, showing robust adoption with 4.4 million daily active addresses and holding $92.3 billion in USDT, nearly half of Tether’s market cap. This growth is supported by reduced smart contract...
Arbitrum's token ARB surged 51.6% in the last 24 hours and 123.8% over the past week, standing out as the top performer in a mostly steady crypto market where Bitcoin and Ethereum posted modest gains. This sharp rise is linked to renewed community en...
Robinhood chose to build its blockchain using Arbitrum technology, allowing it to retain about 90% of net protocol revenue after costs and revenue sharing, unlike if it had deployed on Solana where it would only earn application-level fees. This deci...
